TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$36.36-0.71%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · TEVA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 32.1% |
| Our one-year growth estimate | diamond | 16.6% |
Growth built into the price is above our model estimate.
The price assumes 15.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
TEVA — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-09-03
Material Modification to Rights of Security Holders. On August 31, 2026, Teva Pharmaceutical Industries Ltd. (the “ Company ”) executed an amendment (such amendment, the “ Amendment No. 1 ”) to the Second Amended and restated Deposit Agreement, dated as of December 4, 2018, among the Company, Citibank, N.A., as depositary (the “ Depositary ”) and all holders and beneficial owners of American depositary shares (“ ADSs ”) issued thereunder, and updated the form of American depositary receipt (t…
Why it matters: Free cash flow of $2.0-$2.4 billion shows Teva is financially healthy and efficient.
Supportive ifFree cash flow reported between $2.0-$2.4 billion for 2026.
Worry ifFree cash flow below $2.0 billion shows financial difficulties.
Why it matters: Another earnings beat would build confidence in Teva's recovery. A miss could signal ongoing challenges.
Watch forQ2 earnings exceed analyst expectations as they did in Q1.
Also watch forQ2 earnings fall short of analyst expectations.
Why it matters: This target matters for checking how much money Teva makes. Missing it raises worries about how well they run their operations.
Supportive ifAdjusted EBITDA is between $5.0 billion and $5.3 billion for 2026.
Worry ifAdjusted EBITDA is less than $5.0 billion.
Why it matters: If healthcare sector growth speeds up, it could benefit Teva's performance.
Supportive ifHealthcare sector revenue growth returns to above 10% year over year.
Worry ifHealthcare sector revenue growth stays below 5% year over year.
Why it matters: Good results from duvakitug studies could support Teva's plans and help future growth.
Supportive ifEnrollment for Phase 3 studies for duvakitug is on track with good interim results.
Worry ifPhase 3 studies for duvakitug may have big delays or bad interim results.
Why it matters: Biosimilars are a key growth area for Teva. Strong revenue growth shows good market success.
Supportive ifBiosimilars revenue is over $200 million in Q3 2026.
Worry ifBiosimilars revenue falls below $150 million in Q3 2026.
Why it matters: Approval would help Teva's new products and increase revenue in the CNS area.
Supportive ifOlanzapine LAI receives FDA approval for launch in Q4 2026.
Worry ifOlanzapine LAI does not receive FDA approval by the end of Q4 2026.
Why it matters: Growth in these brands shows Teva's success in its Pivot to Growth strategy. It affects overall revenue and investor confidence.
Supportive ifKey brands grow over 40% each year in Q3 2026.
Worry ifKey innovative brands show less than 30% growth year over year in Q3 2026.
Why it matters: Updates on this submission will show progress in Teva's neuroscience work and revenue.
Supportive ifFDA accepts the NDA for ecopipam. This shows progress in the approval process.
Worry ifFDA rejects or delays the NDA for ecopipam beyond Q4 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$123 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $327 loss on $10,000 · 3.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,179 loss on $10,000 · 21.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.